IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance

Go back to IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
(NASDAQ: ICCM) Delayed: 2.23 +0.03 (1.36%)
Previous Close $2.20    52 Week High
Open $2.20    52 Week Low
Day High $2.25    P/E N/A 
Day Low $2.13    EPS
Volume 58,440